Indivior Signals Strong Growth with Ambitious 2026 Financial Guidance

RICHMOND, VA – January 08, 2026 – Indivior PLC has issued a robust full-year 2026 financial forecast, signaling a period of significant growth and enhanced profitability driven by its flagship opioid use disorder (OUD) treatment, SUBLOCADE®, and a sweeping operational overhaul. The company projects total net revenue to reach between $1.125 billion and $1.195 billion, with adjusted EBITDA expected to surge by 35%.

This optimistic guidance arrives as Indivior executes a multi-phase strategic plan, shifts its corporate domicile to the United States, and closes the book on a major legacy legal issue, collectively painting a picture of a company repositioning itself for market leadership and renewed investor confidence.

“2025 was a transition year for Indivior in which we established the Indivior Action Agenda and completed Phase I – Generate Momentum,” said Joe Ciaffoni, Chief Executive Officer. “We enter 2026 well positioned to execute on Phase II – Accelerate – which includes accelerating U.S. SUBLOCADE dispense unit growth and SUBLOCADE net revenue throughout 2026 and immediately accelerating adjusted EBITDA and cash flow at a faster rate.”

SUBLOCADE: The Engine of Growth

The cornerstone of Indivior's bullish outlook is SUBLOCADE, a once-monthly injectable for moderate to severe OUD. The company anticipates the drug will generate between $905 million and $945 million in net revenue in 2026, an 11% increase at the midpoint over the previous year. This growth is not just a passive expectation; it's the result of a concerted strategic push.

Already positioned as the leading prescribed long-acting injectable OUD treatment, SUBLOCADE's momentum is being actively fueled. In late 2025, Indivior launched its first national direct-to-consumer (DTC) advertising campaign, titled "Move Forward in Recovery." The campaign, which includes television spots, is designed to increase patient awareness and encourage individuals to discuss the treatment option with their healthcare providers. This marketing effort builds on a solid foundation, as U.S. net revenue for the drug had already climbed 14% year-over-year in the third quarter of 2025, driven by higher volumes and favorable gross-to-net adjustments.

Indivior's strategy focuses on accelerating the number of dispense units, a key metric for adoption and market penetration. By investing in patient activation and provider education, the company aims to solidify SUBLOCADE's role as a critical tool in addressing the ongoing opioid crisis.

A Leaner, More Focused Operation

Underpinning the impressive top-line growth is a fundamental transformation of the company's operating model. The 'Indivior Action Agenda' is the blueprint for this change. Phase I, 'Generate Momentum,' which concluded in 2025, involved a deep-cutting simplification of the organization. This included reducing headcount, consolidating the company's physical footprint, discontinuing commercial support for its nasal spray product OPVEE, and optimizing its business in the Rest of World (ROW) markets.

These decisive actions are projected to yield substantial financial benefits, with expected annual non-GAAP operating expense savings of at least $150 million beginning in 2026. This newfound efficiency is directly reflected in the bottom-line guidance.

“Our 2026 financial guidance reflects SUBLOCADE net revenue growth, driven by an acceleration in dispense units, and significant margin expansion from our simplified operating model,” stated Ryan Preblick, Chief Financial Officer. He noted that while growing SUBLOCADE revenue by 11%, the company expects to grow adjusted EBITDA by 35% and expand its adjusted EBITDA margin by a remarkable 14 percentage points.

With Phase II, 'Accelerate,' now underway as of January 1, 2026, the focus shifts to leveraging this leaner structure to drive faster growth in SUBLOCADE sales, adjusted EBITDA, and overall cash flow, creating a more powerful and financially resilient enterprise.

Solidifying a U.S. Identity and Market Presence

Indivior's strategic evolution extends beyond its financial and operational metrics. The company has taken significant steps to align its corporate structure with its primary market. Following shareholder approval, Indivior is set to change its corporate domicile from the United Kingdom to the United States, with the new U.S. parent company, Indivior Pharmaceuticals, Inc., expected to be established on January 26, 2026.

This move is intended to maximize the benefits of its U.S. stock listing on the Nasdaq, expand its presence in American capital markets, and increase the potential for inclusion in major U.S. equity indices. Beyond the financial mechanics, the redomiciliation aims to simplify corporate governance and position Indivior as a U.S.-based innovator, fostering closer collaboration with American public health leaders to advance OUD treatment.

This strategic repositioning was bolstered by a significant market milestone in late 2025. Effective December 22, 2025, Indivior was added to the S&P SmallCap 600® index. Inclusion in this specific index is particularly noteworthy as it employs a strict profitability screen, requiring constituents to have positive earnings in their most recent quarter and over the past year. This achievement serves as an external validation of Indivior's financial viability and is expected to enhance stock liquidity and attract greater institutional ownership.

Turning the Page on Legacy Issues

A final, crucial element of Indivior's renewed trajectory is the resolution of a major historical challenge. The company recently concluded a legacy matter with the U.S. Department of Justice by making a final payment of $295 million, settling its outstanding obligation in full. This payment removes a significant cloud of uncertainty that has lingered over the company, freeing up management focus and financial resources for its core mission.

This resolution, combined with strong historical performance—including a Q3 2025 earnings per share that surpassed analyst expectations by over 84%—and a healthy cash and investments balance of $473 million at the end of that quarter, has significantly de-risked the company's profile for investors.

By systematically addressing operational inefficiencies, legacy legal issues, and its corporate structure, Indivior has cleared the deck. The company now enters 2026 with a clear focus on accelerating the adoption of SUBLOCADE, expanding its profitability, and cementing its leadership role in the critical field of opioid use disorder treatment.